ThursdaySep 09, 2021 11:58 am

QualityStocksNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) to Share Company’s Mission, iSTRYM Developments at 2021 SANA Symposium

MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE”), a leader in advanced proprietary technology and research in psychedelics, today announced its presence at the 2021 SANA Symposium as a platinum sponsor and host of the Innovation Theater. According to the update, MINDCURE will be engaging with clinicians around the world interested in learning more about psychedelic-assisted psychotherapy, and specifically in adopting novel protocols and practice standards around psychedelics. The timing of the conference coincides with the company’s recent release of its digital therapeutics (“DTx”) platform for psychedelics — iSTRYM — into partner clinics across North America. “We could not ask for a better time or…

Continue Reading

WednesdaySep 08, 2021 10:36 am

QualityStocksNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) to Participate in H.C. Wainwright Global Investment Conference

Mind Cure Health (CSE: MCUR) (OTCQB: MCURF), a leader in advanced proprietary technology and research for psychedelics, has announced that it will featured at the upcoming H.C. Wainwright 23rd annual Global Investment Conference. The three-day conference is scheduled to begin Sept. 13 and runs through Sept. 15, 2021. MINDCURE president and CEO Kelsey Ramsden will present an overview of the company on Sept. 13, 2021, at 7 a.m. ET. The presentation will be available for interested viewers for 90 days following the conference. To view the presentation, visit https://ibn.fm/whfnm To view the full press release, visit https://ibn.fm/gmkso About Mind Cure Health…

Continue Reading

TuesdayAug 31, 2021 12:13 pm

QualityStocksNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) Leveraging Strategic Board Appointment to Execute Visionary Strategy

Mind Cure Health (CSE: MCUR) (OTCQB: MCURF), a leader in advanced proprietary technology and research for psychedelics, recently announced its appointment of Jerry White as an advisor to the company. White has been recognized for his efforts in engaging large audiences to power global movements and is a recognized leader of the International Campaign to Ban Landmines and a co-recipient of the 1997 Nobel Peace Prize. Given his expertise, ambition and successful track record, White is an excellent addition to the company’s advisory board as it focusses on achieving strategic goals while working towards its overall vision. “Never shying away…

Continue Reading

ThursdayAug 26, 2021 10:30 am

QualityStocksNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) Releases First-of-Its-Kind Digital Therapeutics Platform to Partner Clinics in North America

Mind Cure Health (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH), a leader in advanced proprietary technology and research for psychedelics, today announced the release of the minimum viable product version of iSTRYM, its digital therapeutics platform (“DTx”) for psychedelics, into partner clinics across North America. According to the update, the company will begin full commercial deployment to all clinics in the first quarter of 2022. MINDCURE intends to target psychedelic clinics initially and to then expand to integrated clinics, both traditional and psychedelic, and eventually to the broader mental health market. The company forecasts 150 clinics in Canada, the U.S. and…

Continue Reading

FridayAug 20, 2021 9:00 am

Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) 2021 Growth Strategy Update

So far in 2021, Mind Cure has embarked on an aggressive plan to strengthen its advisory board and file for new provisional patents for its fully synthetic ibogaine  In January, the company also announced an amended agreement to grow the size of an earlier-announced bought deal financing  This year has also seen the launch of the second stage of manufacturing of Ibogaine for use in psychedelic clinical research  Mind Cure also continues to strengthen its proprietary digital therapeutics technology (“DTx”), iSTRYM All of Mind Cure’s decisions thus far are designed to help the company achieve overall growth and fulfill its vision of easing suffering, increasing productivity, and enhancing mental health  Mind Cure…

Continue Reading

ThursdayAug 19, 2021 11:44 am

QualityStocksNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) Co-Founder, CEO Featured on Bell2Bell Podcast

Mind Cure Health (CSE: MCUR) (OTCQB: MCURF), a leader in advanced proprietary technology and research for psychedelics, has announced that co-founder and CEO Kelsey Ramsden is featured on the latest episode of the Bell2Bell podcast. The Bell2Bell Podcast offers its listeners insightful interviews with executives of companies operating in fast-moving industries. During the episode, hosted by InvestorBrandNetwork’s Stuart Smith, Ramsden provided an overview of the company’s business model and also discussed the changing regulatory and social environments surrounding psychedelic-assisted therapy. She also talked about the company’s current focus: the development of a clinical-grade, evidence-backed, science-based, AI-driven tool to enable therapists…

Continue Reading

TuesdayAug 17, 2021 9:00 am

Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) Welcomes Digital Technology Expert in Development of Doctor-Patient SaaS Tech

Canada-based life sciences company Mind Cure Health is pursuing innovative technology and research solutions to improve mental health through technology  The company is focused on developing digital therapeutics technology and researching psychedelic compounds The company’s proprietary software-as-a-service (SaaS) platform iSTRYM is designed to increase transparency and awareness between patients and therapists  On the research side, Mind Cure Health is also manufacturing synthetic ibogaine and currently determining the commercialization potential of two different pathways for production Mind Cure Health recently announced an agreement with experienced clinical psychologist Dr. Ken Weingardt to guide iSTRYM toward near-term commercial deployment A growing number of…

Continue Reading

FridayAug 13, 2021 9:00 am

Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) Bolsters its Advisory Board With The Appointment of Jerry White

Mind Cure Health Inc. announced Jerry White’s appointment into the company’s advisory board Mr. White brings a wealth of experience from his years of powering global movements and working with key leaders and personalities around the world MINDCURE forecasts that with Mr. White’s addition to the board, the company will be well-positioned to achieve bigger and better goals, all while working towards its overall vision of building mental wealth globally Mind Cure Health (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) announced that it has appointed Jerry White as an advisor to the company. Mr. White would be an excellent addition to…

Continue Reading

TuesdayAug 10, 2021 9:51 am

QualityStocksNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) Names Digital Therapy Visionary as Tech Advisor

Mind Cure Health (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH), a leader in advanced proprietary technology and research for psychedelics, has announced that Dr. Ken Weingardt, CEO of Audacious Digital Health, will be serving as senior clinical technology advisor. Weingardt is a clinical psychologist and has served as senior clinical director at Pear Therapeutics. Specifically,  Weingardt will work with MINDCURE's iSTRYM, the company’s digital therapeutics technology (“DTx”) platform, through near-term commercial deployment. iSTRYM is on schedule for MVP deployment in the third quarter of 2021, with commercial deployment slated for first quarter 2022. Weingardt , who most recently served as the director…

Continue Reading

WednesdayAug 04, 2021 9:33 am

QualityStocksNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) Names Nobel Peace Prize Recipient as Company Advisor

Mind Cure Health (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH), a leader in advanced proprietary technology and research for psychedelics, has appointed Jerry White as a company advisor. A passionate activist, author and social entrepreneur, White is the recipient of numerous human rights and leadership awards, including sharing the Nobel Peace Prize in 1997. In his new role, White will advise MINDCURE on its mission to revolutionize mental health treatments worldwide through the development and scaling of science-backed psychedelic medicine. White shares in the 1997 Nobel Prize for Peace, which was awarded to the International Campaign to Ban Landmines, an organization that he…

Continue Reading

Market Basics

New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

The Basics

Newsletter Publishers

Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

Register

Public Companies

Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

Get Covered